Benitec Biopharma’s (BNTC) Buy Rating Reiterated at HC Wainwright

Benitec Biopharma (NASDAQ:BNTC)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $28.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 73.81% from the company’s previous close.

A number of other research analysts also recently commented on BNTC. Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research note on Thursday, December 12th. Robert W. Baird initiated coverage on Benitec Biopharma in a report on Friday, December 13th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $17.00 target price on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.43.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $16.11 on Monday. Benitec Biopharma has a 1-year low of $4.75 and a 1-year high of $16.90. The stock has a market cap of $377.80 million, a P/E ratio of -10.67 and a beta of 0.92. The firm has a 50-day moving average of $11.91 and a two-hundred day moving average of $10.97.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. As a group, equities analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Benitec Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of BNTC. Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma in the 3rd quarter worth approximately $274,000. Ameriprise Financial Inc. lifted its stake in Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after buying an additional 20,597 shares during the last quarter. 683 Capital Management LLC bought a new stake in Benitec Biopharma in the fourth quarter valued at $452,000. Northern Trust Corp boosted its holdings in shares of Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after acquiring an additional 13,425 shares during the period. Finally, MYDA Advisors LLC bought a new position in shares of Benitec Biopharma during the fourth quarter worth about $632,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.